spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  SPD503 

 HSMN NewsFeed - 16 Oct 2007
FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Shire Divests Non-Core Product Portfolio to Almirall
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 21 Jun 2007
Shire Receives Approvable Letter From FDA for INTUNIV(TM) (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jun 2007
Shire In-Licenses JUVISTA(R) (Human TGFbeta3) From Renovo
Biopharmaceuticals Licensing
 HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 May 2007
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of LIALDA(TM) (mesalamine) Presented at DDW
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 May 2007
FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 May 2007
VYVANSE(TM) (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2007
Shire Completes Acquisition of New River
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Apr 2007
Shire Successfully Completes Tender Offer for New River Shares
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Mar 2007
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 Mar 2007
Shire Begins External Search for President of Successful Human Genetic Therapies Business, on Retirement of David Pendergast at the End of 2007
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2007
LIALDA(TM) (mesalamine) With MMX(TM) Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Mar 2007
UK Launch Expands Global Reach of FOSRENOL(R)
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2007
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 16 Jan 2007
FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Dec 2006
New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
Dr. Jeffrey Leiden Appointed Non Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2006
FOSRENOL(R) Data Show Evidence of Trends Towards Improved Bone Formation in CKD Stage 5 Patients, New Data Presented at ASN Meeting
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of a Meta-Analysis Comparing Stimulant Medications to Non-Stimulant Medications in Treating ADHD in Patients Aged 8 to 15
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2006
Shire Sues Andrx Pharmaceuticals, L.L.C.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2006
ELAPRASE(TM) (idursulfase) Receives Positive Opinion in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Sep 2006
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 24 Aug 2006
Shire Announces NDA Submission of Guanfacine Extended Release for the Treatment of ADHD in Children and Adolescents
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Aug 2006
Shire and Barr Settle All Pending Litigation Concerning ADDERALL XR(R) and enter into Development and License Agreement
Biopharmaceuticals Generics Litigation Licensing
 HSMN NewsFeed - 24 Jul 2006
Shire's ELAPRASE(TM) (idursulfase) Approved by the Food and Drug Administration (FDA) for Hunter Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jun 2006
Shire's DAYTRANA(TM), First Transdermal Medication for Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children, Now Available in Pharmacies
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Positive Study Results for DAYTRANA(TM) (methylphenidate transdermal system) Presented at a Major Medical Meeting
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 21 Apr 2006
FOSRENOL(r) Significantly Reduces Tablet Burden for End-Stage Renal Disease Patients With Hyperphosphatemia and Improves Patient and Physician Satisfaction, a New Study Reports
Biopharmaceuticals
 HSMN NewsFeed - 6 Apr 2006
Shire's DAYTRANA(TM) Transdermal Patch Approved by FDA for Treatment of ADHD
Biopharmaceuticals FDA Drug Delivery
 HSMN NewsFeed - 10 Mar 2006
Shire Announces Status of Ongoing FDA Review of NDA for DAYTRANA(TM) for the Treatment of ADHD
Biopharmaceuticals FDA Drug Delivery
 HSMN NewsFeed - 3 Mar 2006
Shire Sues Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 3 Feb 2006
Shire Announces European Filings of SPD476 (Mesalazine) for Treatment of Ulcerative Colitis
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 19 Jan 2006
Shire and Impax Settle all Pending Litigation Concerning ADDERALL XR(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 18 Jan 2006
ADDERALL XR(R) - Paragraph IV Notice Update - Third Notice Letter From Teva Pharmaceuticals USA, Inc.
Biopharmaceuticals Generics
Return to NewsFeed  

 Additional items found! 23

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 23 additional stories matching:
SPD503
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.